IS8447A - Aðferð til að framleiða gamma-karboxýleruð prótín - Google Patents

Aðferð til að framleiða gamma-karboxýleruð prótín

Info

Publication number
IS8447A
IS8447A IS8447A IS8447A IS8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A
Authority
IS
Iceland
Prior art keywords
producing gamma
carboxylated protein
carboxylated
protein
gamma
Prior art date
Application number
IS8447A
Other languages
English (en)
Inventor
Fenge Christel
Lövgren Ann
Thelin Anders
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8447A publication Critical patent/IS8447A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
IS8447A 2003-10-14 2006-05-10 Aðferð til að framleiða gamma-karboxýleruð prótín IS8447A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (1)

Publication Number Publication Date
IS8447A true IS8447A (is) 2006-05-10

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8447A IS8447A (is) 2003-10-14 2006-05-10 Aðferð til að framleiða gamma-karboxýleruð prótín

Country Status (28)

Country Link
US (2) US7842477B2 (is)
EP (2) EP1678297B1 (is)
JP (1) JP4658946B2 (is)
KR (1) KR101201020B1 (is)
CN (2) CN102443548B (is)
AR (1) AR046180A1 (is)
AT (1) ATE491789T1 (is)
AU (2) AU2004281350B2 (is)
BR (1) BRPI0415277A (is)
CA (1) CA2541764C (is)
CO (1) CO5690657A2 (is)
DE (1) DE602004030603D1 (is)
DK (1) DK1678297T3 (is)
ES (2) ES2532470T3 (is)
GB (1) GB0324044D0 (is)
IL (2) IL174633A (is)
IS (1) IS8447A (is)
MX (1) MXPA06004060A (is)
MY (1) MY141859A (is)
NO (1) NO339740B1 (is)
NZ (2) NZ546584A (is)
PL (1) PL1678297T3 (is)
PT (1) PT1678297E (is)
RU (2) RU2372401C2 (is)
TW (1) TWI355419B (is)
UY (1) UY28558A1 (is)
WO (1) WO2005038019A1 (is)
ZA (1) ZA200603038B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380985B1 (en) * 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20090325226A1 (en) * 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1939283A4 (en) * 2005-09-30 2009-02-25 Chemo Sero Therapeut Res Inst PROCESS FOR PRODUCING RECOMBINANT HUMAN THROMBIN BY A CULTIVATED CELL
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US20100159512A1 (en) * 2006-03-06 2010-06-24 Kurt Osther Method for the preparation of recombinant human thrombin and fibrinogen
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
BR112013008034A2 (pt) * 2010-10-06 2016-06-14 Medimmune Ltd método para normalizar hemeostase comprometida
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
WO2013036445A1 (en) 2011-09-06 2013-03-14 Medimmune Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
AU2014369177B2 (en) * 2013-12-20 2017-04-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
JPH03501921A (ja) 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
CA2087970A1 (en) 1990-07-23 1992-01-24 Kathleen L. Berkner Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
ATE455552T1 (de) * 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
CA2315879A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
WO2001007068A1 (en) 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
DE60231210D1 (de) 2001-07-06 2009-04-02 Chemo Sero Therapeut Res Inst Verfahren zur herstelllung von menschlichem thrombin mittels genmodifikationstechnik
US20050164365A1 (en) 2001-07-06 2005-07-28 Juridical Foundation The Chemosero-Therapeutic Research Institute Genetically modified ecarin and process for producing the same
EP1407780B1 (en) 2001-07-10 2013-05-01 The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1676911B1 (en) 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same
JP2008523837A (ja) 2004-12-21 2008-07-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ガンマ―カルボキシル化に欠陥のある宿主系におけるガンマ―カルボキシル化ポリペプチドの発現
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
PL1969127T5 (pl) 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
EP2292748B1 (en) 2014-12-17
US7842477B2 (en) 2010-11-30
CN102443548A (zh) 2012-05-09
MXPA06004060A (es) 2006-06-28
CN1867669B (zh) 2011-10-19
EP1678297B1 (en) 2010-12-15
US20110092429A1 (en) 2011-04-21
ATE491789T1 (de) 2011-01-15
RU2009123931A (ru) 2010-12-27
NO20061470L (no) 2006-05-12
CA2541764C (en) 2015-03-31
IL174633A (en) 2013-06-27
BRPI0415277A (pt) 2006-12-19
TWI355419B (en) 2012-01-01
DK1678297T3 (da) 2011-03-14
CN102443548B (zh) 2014-03-12
PL1678297T3 (pl) 2011-11-30
NZ546584A (en) 2009-08-28
AU2004281350A1 (en) 2005-04-28
AU2008205445A1 (en) 2008-09-04
UY28558A1 (es) 2005-05-31
US20050164367A1 (en) 2005-07-28
WO2005038019A1 (en) 2005-04-28
ES2357603T3 (es) 2011-04-28
ZA200603038B (en) 2007-09-26
CN1867669A (zh) 2006-11-22
AR046180A1 (es) 2005-11-30
IL226313A0 (en) 2013-06-27
KR101201020B1 (ko) 2012-11-14
NO339740B1 (no) 2017-01-30
IL174633A0 (en) 2006-08-20
MY141859A (en) 2010-07-16
TW200523365A (en) 2005-07-16
EP1678297A1 (en) 2006-07-12
AU2004281350B2 (en) 2008-05-15
RU2372401C2 (ru) 2009-11-10
HK1155475A1 (en) 2012-05-18
ES2532470T3 (es) 2015-03-27
JP2007508820A (ja) 2007-04-12
JP4658946B2 (ja) 2011-03-23
CO5690657A2 (es) 2006-10-31
RU2006110147A (ru) 2007-11-20
EP2292748A1 (en) 2011-03-09
CA2541764A1 (en) 2005-04-28
GB0324044D0 (en) 2003-11-19
PT1678297E (pt) 2011-03-15
US8697440B2 (en) 2014-04-15
KR20060123152A (ko) 2006-12-01
DE602004030603D1 (de) 2011-01-27
NZ578306A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
CY2015015I1 (el) Παραγωγη τιακουμυκινης
DK1687066T3 (da) Fremgangsmåder til immunmodulering
DE60205413D1 (de) Herstellungsverfahren
IS8447A (is) Aðferð til að framleiða gamma-karboxýleruð prótín
EE200300420A (et) Vormitiste tootmise meetod
IS8122A (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
PL371629A1 (pl) Sposób wytwarzania kombrestatyn
NO20041150L (no) Fremgangsmate for a danne en sammenfoyning.
DK1691787T3 (da) Fremgangsmåde til at danne småpartikler
IS8416A (is) Aðferð við framleiðslu á CCR-2 mótlyfi
IS7069A (is) Aðferð til að framleiða zaleplon
IS7981A (is) Aðferð til að framleiða örkerfi
DE602004003115D1 (de) Tonerherstellungsverfahren
SE0301664L (sv) Method for compression of data
NO20035626D0 (no) Metode
IS8333A (is) Aðferð við framleiðslu á THIP
NO20035401D0 (no) Metode
IS7339A (is) Aðferð til framleiðslu á 7alfa-metýlsterum
NO20054532D0 (no) Fremgangsmater for a forhindre glukonoylering av proteiner
ITMI20021432A0 (it) Metodo per produrre cefalosporine
EP1760149A4 (en) PROCESS FOR CONSTRUCTING MODIFIED PROTEIN
IS6928A (is) Aðferðir til að framleiða mirtasapínmilliefni
NO20035692D0 (no) Produksjonsmetode
ITTO20030359A1 (it) Metodo di produzione di focacce farcite.
PL359838A1 (pl) Sposób wytwarzania nano-ścieżek